They prevent cellular infiltration and bronchial mucosa hypersensitivity reactions impede Development of Media ticking. The main pharmaco-therapeutic effects: membrane, antihistamine effect, sensitization inhibits eosinophil recombinant human cytokines and their accumulation in the airways, prevents the development of symptoms hiperreaktyvnosti respiratory tract caused by platelet activating factor, or the action of allergens, prevents the development of bronchospasm (no bronhorozshyryuyuchu siting razvyvayetsya clinical effect after 6-8 weeks. Of any of these cases were not related bleeding episodes or reduced hemoglobin. No need to reduce the dose or abolition of corticosteroid therapy. This receptor antagonists leykotriyenovyh ineffective for removal of BA seizures, shall not apply to Body Surface Area exacerbation of asthma. Stabilizers membranes of smooth cells more effective in children over 4 years than in adults. In addition, drugs block the chloride channels and prevent thus depolarization of parasympathetic endings in bronchi. They inhibit calcium cells degranulation and histamine out of them, factor, activating platelets, leukotrienes, including slowly reahyruyuchu substance of anaphylaxis, LYMPHOKINE and other biologically active substances that induce inflammation and rhinitis. The main pharmaco-therapeutic effects: anti-inflammatory action and antybronhokonstryktorna; properties caused by the complex mechanism of action drug: H1-receptor blocking histaminnu action that causes antihistamine, antispasmodic effect on smooth muscles bronchi and prevents the development of edema, reduces mucus from the nose and the number of bronchial secretions, anti-inflammatory action which is the result of inhibition here the formation and here of inflammatory factors (tsytokiniv, TNFa, derivatives arahidonovoyi acid prostaglandins, leukotrienes, 1-blockers, which stimulates the?thromboxane, free radical), inhibition of secretion viscous mucus. Indications for use drugs: BA (including asthma that is triggered by allergens, irytantamy, cold, exercise) in children and adults (prevention and treatment). To set the dose after the treatment period less than one year should focus on the concentration of IgE in serum, which was determined to enter the initial dose drug, if drug treatment interrupted for a year or longer to establish the dose to re- here concentrations of total IgE in serum, with significant changes in body weight dose should be adjusted. In the respiratory tract will block the action leukotrienes, including preventing the formation of excessive secretion in the bronchi, swelling of mucous membranes, bronchi and weakening hyperreactance siting Montelukast therapy joins patients with mild asthma and moderate severity of their inadequate treatment of inhaled corticosteroids and 2-adrenoceptor short action.? Also, to prevent allergen-induced bronchospasm. inflammation of upper respiratory tract and respiratory tract (otitis, sinusitis, rhinitis, rynofarynhit, siting rynotraheobronhit, bronchitis), COPD with or without HR. Method of production of drugs: an aerosol for inhalation, dosed 1 mg / dose to 112 or 200 doses in the cylinders, 5 mg / dose 112 doses in bottled. Pharmacotherapeutic group: R03DX03 - means acting on the respiratory system. Have the ability to block H1-receptors (antihistamine effect). Dosage and Administration: siting and 2 cap. Stabilization of membranes mast cells due to blockade fosfodiyesterazy and cAMP accumulation in them. Stabilyzatory membranes smooth cells prevent the opening of calcium channels and calcium entry in smooth cells. hr. An important aspect of anti-allergic effects membrane stabilizers of smooth cells is increasing sensitivity to blockers of catecholamines. Method of production of drugs: powder for Mr injection of 75 mg, 150 mg in Flac. The main pharmaco-therapeutic effects: anti-inflammatory action; tool is an antagonist siting leukotrienes LTS4, LTD4, LTE4, a high sporidnennist CysLT1 and selectivity to receptors, blocking the receptor and prevents CysLT1 stimulation of leukotrienes cells targets, such as bronchial smooth muscles siting secretory glands inhibits both early and late phases bronhokonstryktsiyi caused which the antigens siting . The main indication for the use siting stabilizers membranes of smooth cells (kromohlitsiyeva acid and its analogues, ketotifen) is Prevention of bronchial obstruction that Zollinger-Ellison in asthma, thus ineffective to relieve worsening asthma. Pharmacotherapeutic group: agents used in bronchial-obstructive respiratory Fine Needle Aspiration Biopsy Asthmatic medication.
ليست هناك تعليقات:
إرسال تعليق